Immunomodulator compounds and methods of use
US-2018177870-A1 · Jun 28, 2018 · US
Imidazopyridazine and imidazopyridine compounds and uses thereof
US12030889B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12030889-B2 |
| Application number | US-202217836602-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 9, 2022 |
| Priority date | Dec 20, 2018 |
| Publication date | Jul 9, 2024 |
| Grant date | Jul 9, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound which is 5-(7-(1-Isopropyl-1H-pyrazol-4-yl)-6-methylimidazo[1,2-b]pyridazin-3-yl)-2-(pyrimidin-2-yl)-1,8-naphthyridine. 2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or excipient. 3. A compound which is 5-(7-(1-Isopropyl-1H-pyrazol-4-yl)-6-methylimidazo[1,2-b]pyridazin-3-yl)-2-(pyrimidin-2-yl)-1,8-naphthyridine, or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof, and an pharmaceutically acceptable carrier or excipient. 5. A compound which is 1-(4-(3-(7-(1-Ethyl-1H-imidazol-4-yl)-1,8-naphthyridin-4-yl)-6-methylimidazo[1,2-b]pyridazin-7-yl)phenyl)-N,N-dimethylmethanamine. 6. A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier or excipient. 7. A compound which is 1-(4-(3-(7-(1-Ethyl-1H-imidazol-4-yl)-1,8-naphthyridin-4-yl)-6-methylimidazo[1,2-b]pyridazin-7-yl)phenyl)-N,N-dimethylmethanamine, or a pharmaceutically acceptable salt thereof. 8. A pharmaceutical composition comprising the compound of claim 7 , or a pharmaceutically acceptable salt thereof, and an pharmaceutically acceptable carrier or excipient. 9. A compound which is 1-(4-(6-methyl-3-(7-(4-methyl-2H-1,2,3-triazol-2-yl)-1,8-naphthyridin-4-yl)imidazo[1,2-b]pyridazin-7-yl)benzyl)piperidin-4-ol. 10. A pharmaceutical composition comprising the compound of claim 9 and a pharmaceutically acceptable carrier or excipient. 11. A compound which is 1-(4-(6-methyl-3-(7-(4-methyl-2H-1,2,3-triazol-2-yl)-1,8-naphthyridin-4-yl)imidazo[1,2-b]pyridazin-7-yl)benzyl)piperidin-4-ol, or a pharmaceutically acceptable salt thereof. 12. A pharmaceutical composition comprising the compound of claim 11 , or a pharmaceutically acceptable salt thereof, and an pharmaceutically acceptable carrier or excipient.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
- C07D519/00Primary
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12030889B2 cover?
- Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
- Who is the assignee on this patent?
- Incyte Corp
- What technology area does this patent fall under?
- Primary CPC classification C07D519/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).